Evidence map›Paper›PMID 34176105›Full record

ReviewAnnals of nuclear medicine2021

Jianpeng Cao, Yue Chen, Mei Hu, Wei Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. FDG/PSMA discordance in [Frontiers in oncology · 2026
    Review
  2. Article
  3. Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jianpeng CaoDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25 TaiPing St, Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.
Yue ChenDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25 TaiPing St, Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.
Mei HuDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25 TaiPing St, Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China.
Wei ZhangDepartment of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, No. 25 TaiPing St, Jiangyang District, Luzhou, 646000, Sichuan, People's Republic of China. zhangwscd@163.com.

Funding

Sichuan Province Science and Technology Support Program No 2020ZYD101
6 · The paper itself

Abstract

The prevalence of metastatic castration-resistant prostate cancer (mCRPC) is increasing, and its prognosis is often poor. As a highly expressed target in mCRPC, prostate-specific membrane antigen (PSMA) is very attractive for its diagnosis and treatment. When the efficacy of chemical therapy is limited, radioligand therapy (RLT)-based on Lutetium-177 (

Indexed as

Glutamate Carboxypeptidase IILutetiumNeoplasm MetastasisProstatic Neoplasms, Castration-ResistantRadioisotopesAntigens, SurfaceHumansMaleAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILutetiumLutetium-177Radioisotopes177LuLimitationsmCRPCProstate-specific membrane antigen (PSMA)Radioligand therapy (RLT)

Identifiers

PMID34176105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.